Vistagen is a late-stage clinical biotech company developing a new class of intranasal drugs called pherines to treat central nervous system disorders. Unlike traditional neuropsychiatric medications that bind to receptors in the brain, Vistagen's pherine compounds target peripheral sensory neurons in the nasal cavity to modulate brain circuits without systemic absorption into the bloodstream. The company's lead candidate, fasedienol, is a nasal spray in Phase 3 clinical development for the acute, as-needed treatment of social anxiety disorder. Vistagen designed fasedienol for situational use during anxiety-provoking events rather than as a daily maintenance therapy. The company’s pipeline also includes itruvone for major depressive disorder and refisolone for menopausal hot flashes, both of which have completed Phase 2a trials. As a pre-commercial entity, Vistagen generates no product revenue and funds its R&D operations through equity and debt financing. The company's business model relies on achieving clinical milestones and FDA approval to support independent commercialization or regional licensing. Vistagen has already established a partnership with AffaMed for fasedienol in Greater China and Southeast Asia. The company's regulatory path currently depends on positive results from its PALISADE-4 Phase 3 study to support a potential marketing application.